capromorelin capromorelin capromorelin, sold under the brand names, entyce and elura, is a medication used for the management of weight loss in cats and dogs. capromorelin is a ghrelin receptor agonist known to increase appetite and weight gain. capromorelinclinical datatrade namesentyce, eluraother namescp-424,391license data us dailymed: capromorelin routes ofadministrationby mouthatcvet codeqh01ax90 (who) legal statuslegal status us: ℞-only pharmacokinetic dataelimination half-life2.4 hoursidentifiers iupac name n-pyridin-5-yl]-1-oxo-3-(phenylmethoxy)propan-2-yl]-2-amino-2-methylpropanamide cas number193273-66-4 npubchem cid216208drugbankdb15205 ychemspider187411 yunii0mq44vun84keggd03373chemblchembl113313 ycomptox dashboard (epa)dtxsid5057886 chemical and physical dataformulac28h35n5o4molar mass505.619 g·mol−13d model (jsmol)interactive image smiles cc(c)(c(=o)n(cocc1=cc=cc=c1)c(=o)n2ccc3=nn(c(=o)3(c2)cc4=cc=cc=c4)c)n inchi inchi=1s/c28h35n5o4/c1-27(2,29)25(35)30-22(18-37-17-21-12-8-5-9-13-21)24(34)33-15-14-23-28(19-33,26(36)32(3)31-23)16-20-10-6-4-7-11-20/h4-13,22h,14-19,29h2,1-3h3,(h,30,35)/t22-,28-/m1/s1 ykey:kvllhlwbpncvnr-skcuwotosa-n y ny (what is this?) (verify) capromorelin was developed by pfizer. capromorelin was approved for veterinary use in the united states in may 2016. it is the second drug approved for the management of weight loss in cats and the first drug approved specifically for the management of weight loss in cats with chronic kidney disease. research capromorelin functions to stimulate the secretion of growth hormone and as a ghrelin mimetic which causes the body to secrete human growth hormone in a way usually seen at puberty and in young adulthood. studies have shown the drug to directly raise insulin growth factor 1 (igf-1) and growth hormone levels. in a one-year treatment trial (starting 1999) with 395 seniors between 65 and 84 years old, patients who received the drug gained an average of 3 lb (1.4 kg) in lean body mass in the first six months and also were better able to walk in a straight line in a test of balance, strength and coordination. after 12 months, patients receiving capromorelin also had an improved ability to climb stairs, however the results were not good enough to continue the trial for the 2nd planned year. as of 2017, capromorelin studies in humans had been discontinued. veterinary uses capromorelin is indicated for the management of weight loss in cats and dogs.